ArticleEuropean radiology2020
A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Diagnostic value of radiomics in predicting Ki-67 and cytokeratin 19 expression in hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Artificial intelligence in hepatocellular carcinoma diagnosis and AI-assisted treatment support: Current landscape and future directions.Liver research (Beijing, China) · 2026Review
- Beyond Diagnosis: Magnetic Resonance Imaging-Based Imaging Biomarkers for Tumor Biology, Prognosis, and Clinical Decision-Making in Hepatocellular Carcinoma.Korean journal of radiology · 2026Review
- Differentiating cholangiocyte phenotype hepatocellular carcinoma and assessing early recurrence risk using contrast-enhanced ultrasound features and clinical indicators.Abdominal radiology (New York) · 2026Article
- CK7-positive hepatocellular carcinoma represents a distinct subtype: a retrospective cohort study.BMC cancer · 2026Article
- Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.European radiology · 2026Review
- Comparative Analysis of Clinical and MR Imaging Characteristics between Dual-Phenotype Hepatocellular Carcinoma and Conventional Hepatocellular Carcinoma: A Retrospective StudyCurrent medical imaging · 2026Article
- Prediction of Histopathological Grade of Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Radiomics Features.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Three-dimensional MR elastography-based stiffness for assessing the status of Ki67 proliferation index and Cytokeratin-19 in hepatocellular carcinoma.European radiology · 2025Article
- Noninvasive Tumor Profiling: Quantitative Contrast-Enhanced MRI Markers Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma.Radiology · 2025Article
- Comparing the computed tomography radiologic features of cytokeratin 19-positive hepatocellular carcinoma to those of conventional hepatocellular carcinoma and intrahepatic cholangiocarcinoma.Quantitative imaging in medicine and surgery · 2025Article
- Deep Reinforcement Learning for CT-Based Non-Invasive Prediction of SOX9 Expression in Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- A magnetic resonance image-based deep learning radiomics nomogram for hepatocyte cytokeratin 7 expression: application to predict cholestasis progression in children with pancreaticobiliary maljunction.Pediatric radiology · 2025Article
- Article
- Habitat radiomics and deep learning on gadoxetic acid-enhanced MRI for noninvasive assessment of CK19 expression and recurrence-free survival in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC.Frontiers in immunology · 2025Article
- Radiomics and Deep Learning as Important Techniques of Artificial Intelligence - Diagnosing Perspectives in Cytokeratin 19 Positive Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Review
- Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.Heliyon · 2024Review
- [A deep learning model based on magnetic resonance imaging and clinical feature fusion for predicting preoperative cytokeratin 19 status in hepatocellular carcinoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma.Abdominal radiology (New York) · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesWe aimed to develop a radiomics-based model derived from gadoxetic acid-enhanced MR images to preoperatively identify cytokeratin (CK) 19 status of hepatocellular carcinoma (HCC).
methodsA cohort of 227 patients with single HCC was classified into a training set (n = 159) and a time-independent validated set (n = 68). A total of 647 radiomic features were extracted from multi-sequence MR images. The least absolute shrinkage and selection operator regression and decision tree methods were utilized for feature selection and radiomics signature construction. A multivariable logistic regression model incorporating clinico-radiological features and the fusion radiomics signature was built for prediction of CK19 status by evaluating area under curve (AUC).
resultsIn the whole cohort, 57 patients were CK19 positive and 170 patients were CK19 negative. By combining 11 and 6 radiomic features extracted in arterial phase and hepatobiliary phase images, respectively, a fusion radiomics signature achieved AUCs of 0.951 and 0.822 in training and validation datasets. The final combined model integrated a-fetoprotein levels, arterial rim enhancement pattern, irregular tumor margin, and the fusion radiomics signature, with a sensitivity of 0.818 and specificity of 0.974 in the training cohort and that of 0.769 and 0.818 in the validated cohort. The nomogram based on the combined model showed satisfactory prediction performance in training (C-index 0.959) and validation (C-index 0.846) dataset.
conclusionsThe combined model based on a fusion radiomics signature derived from arterial and hepatobiliary phase images of gadoxetic acid-enhanced MRI can be a reliable biomarker for CK19 status of HCC. KEY POINTS: • Arterial rim enhancement pattern and irregular tumor margin on hepatobiliary phase on gadoxetic acid-enhanced MRI can be useful for evaluating CK19 status of HCC. • A radiomics-based model performed better than the clinico-radiological model both in training and validation datasets for predicting CK19 status of HCC. • The nomogram based on the fusion radiomics signature can be easily used for CK19 stratification of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.